NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Ketchum K, Peterson K, Thakurta S, et al. Drug Class Review: Newer Antiplatelet Agents: Final Update 2 Report [Internet]. Portland (OR): Oregon Health & Science University; 2011 Jun.

Cover of Drug Class Review: Newer Antiplatelet Agents

Drug Class Review: Newer Antiplatelet Agents: Final Update 2 Report [Internet].

Show details

Appendix FStrength of evidence

Table 1. Acute coronary syndrome: Clopidogrel/aspirin compared with placebo/aspirin (CURE – 12 months)

Table 2. Acute coronary syndrome: clopidogrel compared with aspirin (CAPRIE MI subgroup – 1–3 years [mean 1.9 years])

Table 3. Acute coronary syndrome: Clopidogrel/aspirin compared with placebo/aspirin (CHARISMA symptomatic subgroup – median 28 months)

Table 4. Coronary revascularization: Prasugrel compared with clopidogrel (TRITON-TIMI 38, JUMBO-TIMI 26, PRINCIPLE-TIMI 44)

Table 5. Coronary revascularization: Ticlopidine/aspirin compared with clopidogrel/aspirin (CLASSICS – 28 days)

Table 6. Coronary revascularization: Ticlopidine/aspirin compared with clopidogrel/aspirin (Di Pasquale 2005 – 6 months)

Table 7. Coronary revascularization: Ticlopidine/aspirin compared with clopidogrel/aspirin (Mueller 2003 – 4-week treatment period, 28-month event rates)

Table 8. Coronary revascularization: Ticlopidine/aspirin compared with clopidogrel/aspirin (Mueller 2000 – 30 days)

Table 9. Coronary revascularization: Ticlopidine/aspirin compared with clopidogrel/aspirin (Taniuchi 2001 – 2-week treatment period, 30-day event rates)

Table 10. Stroke or transient ischemic attack: Extended-release dipyridamole plus aspirin compared with clopidogrel plus aspirin (PRoFESS trial)

Table 11. Stroke or transient ischemic attack: Clopidogrel plus aspirin compared with ticlopidine plus aspirin

Table 12. Stroke or transient ischemic attack: Fixed combination of extended-release dipyridamole compared with aspirin alone

Table 13. Stroke or transient ischemic attack: Clopidogrel compared with aspirin alone

Table 14. Stroke or transient ischemic attack: Clopidogrel plus aspirin compared with aspirin alone (FASTER trial)

Table 15. Stroke or transient ischemic attack: Ticlopidine compared with aspirin alone

Table 16. Peripheral vascular disease: Clopidogrel compared with aspirin (PAD subgroup from CAPRIE)

Table 17. Peripheral vascular disease: Clopidogrel plus aspirin compared with aspirin alone (CASPAR trial)

Table 18. Key Question 3 – therapy duration: Clopidogrel vs. placebo: 30-days vs. 12 months (PCI-CURE)

Table 19. Key Question 3 – therapy duration: Clopidogrel vs. placebo: 28-days vs. 12 months (CREDO)

Table 20. Key Question 3 – therapy duration: Pooled analysis of clopidogrel vs. placebo: 1 month vs. 6 months (Akbulut 2004 n=78, Pekdemier 2003 n=278, Bernardi 2007 n=921)

Copyright © 2011 by Oregon Health & Science University.
Bookshelf ID: NBK61807

Views

Other titles in this collection

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...